1. Scrip
  2. >>R&D
  3. >>Clinical Trials

'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

 
• By Mandy Jackson

Acceleron/Celgene’s drug was effective across all endpoints in transfusion-dependent beta-thalassemia and myelodysplastic syndromes, but Acceleron CEO Habib Dable notes key secondary endpoints could be most meaningful to doctors treating these patients.

3-D Rendering Red Blood Cells

Luspatercept met the primary endpoints in its first two Phase III tests – in transfusion-dependent beta-thalassemia and myelodysplastic syndromes (MDS) in the BELIEVE and MEDALIST studies, respectively – but Acceleron Pharma Inc. CEO Habib Dable pointed to key secondary endpoints in both clinical trials that could be the most important data points to treating physicians.

Results from the two studies were presented on Dec. 1 and 2 at the American Society of Hematology (ASH) annual meeting in San Diego. Luspatercept – a first-in-class erythroid maturation agent (EMA), which is believed to regulate late-stage red blood cell maturation – is being developed by Acceleron in partnership with Celgene Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.